Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase 1/2 14Phase NA 12Phase 1 9Phase 3 8Phase 2/3 3Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Skin Neoplasms 2Thymic aplasia 1Neoplasms 1Leukemia, Myeloid, Acute 1Immunologic Deficiency Syndromes 1

Interventions

Cytarabine 11Idarubicin 6fludarabine 5venetoclax 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4posaconazole 3fludarabine phosphate 2Micafungin 2Gemtuzumab 2Filgrastim 2Decitabine 2Daunorubicin 2ruxolitinib 1olutasidenib 1molgramostim 1eltrombopag 1aldesleukin 1aclacinomycins 1Transplantation, Homologous 1Topotecan 1Tobacco Use Cessation Devices 1Thiotepa 1Stem Cell Transplantation 1Safety 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myeloid, Acute × Cyclosporine × Clear all
NCT03150134 2017-05-12

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 4 Unknown
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡